Blog

Russ Greiner’s Team “PC LEARN”, tied for 1st in the Prostate Cancer DREAM Challenge

Competing with 50 teams from around the world in the Prostate Cancer DREAM Challenge, University of Alberta’s PC LEARN team tied for 1st in one of the 3 sub-challenges
to predict the survival and toxicity of Docetaxel treatment in patients with metastatic castrate resistant prostate cancer!

“The DREAM Challenge was an exciting opportunity for us to apply machine learning to real medical data and possibly to contribute to medical research.” said lead PI and APCaRI member Russ Greiner.

The primary benefit of this Challenge will be to establish new quantitative benchmarks for prognostic modeling in mCRPC, with a potential impact for clinical decision making and ultimately understanding the mechanism of disease progression. https://www.synapse.org/#!Synapse:syn2813558/wiki/70844

Stay Informed

To stay up to date on all the latest news and publications, subscribe to our newsletter!

New platform for prostate cancer diagnosis to be presented at ISEV 2017

The Lewis Research Group will present exciting results about new blood tests for prostate cancer during 3 talks at the upcoming 2017 International Society of Extracellular Vesicles (ISEV) annual meeting in Toronto (May 18-21). ISEV is a global society of researchers studying exosomes and microvesicles, which are the exciting new focus of cancer therapy and diagnosis.

Dr. Desmond Pink will speak about “Microflow cytometry: The Apogee A50 is a sensitive standard tool for extracellular vesicle analyses in liquid biopsies”, Robert Paproski’s presentation is entitled “Using machine learning of extracellular vesicle flow cytometry to build predictive fingerprints for prostate cancer diagnosis”, and Dr. John Lewis will speak about “An extracellular vesicle blood fingerprint distinguishes between patients with indolent and aggressive prostate cancer at diagnosis”.

The team is looking forward to sharing these key advances that were made possible through the APCaRI prospective cohort.

- John Lewis